|Day Low/High||149.15 / 150.64|
|52 Wk Low/High||126.10 / 154.50|
"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...
J&J has the potential to 'blow out' Actelion's high blood pressure drug, says Jim Cramer.
Johnson & Johnson is buying the Swiss biotech Actelion for $30 billion.
Johnson & Johnson plans to spin out Actelion's research and development unit into a separate business.
The most logical path for Johnson & Johnson in the next 12 months appears to be sideways or down.
Too many traders overthink market action rather than embrace the momentum and look for reasons to enjoy the upside.
The Dow Jones Industrial Average took almost 103 years to reach 10,000 in March 1999 and nearly 18 more years to reach 20,000.
I'd like to see confirmation of this reversal tomorrow, but now I would "stick my neck out" and write puts.
Half the Dow components have reported and it's their impressive results that are driving indices up.
Jim Cramer says the Dow hitting 20,000 is different from previous big runs because the milestone comes during earnings season and allows traders to reevaluate.
The Dow Jones Industrial Average sports double-digit gains for the first time in three weeks, moving it closer to 20,000.
Today's market has ignored disappointing profit results at 3M (down $3), Johnson & Johnson (down $3) and Verizon (down $2.50), among others. The "reflation" trade appears to be back (in part a function of several predictable executive orders by ...
Jim Cramer thought Johnson & Johnson's results were decent but he remains cautious on pharma.
Johnson & Johnson posted better-than-expected fourth-quarter 2016 earnings amid lower 2017 forecasts.
The following companies (hat tip Zero Hedge) missed on the top line (sales) this morning (profits weren't much better): Johnson & Johnson MMM DuPont Kimberly-Clark Verizon Again, for emphasis -- beware of the bullish narrative of an improving profit...
Dow Jones Industrial Average member Johnson & Johnson is lower in pre-market trading. The reason? The drug maker took a page out of IBM's playbook by recording a much lower effective tax rate in the quarter (14.5% vs. 18%), which on an adjusted basi...
On Tuesday, January 24, investors await a host of quarterly earnings reports.
For the week of January 23, investors will be watching Donald Trump's first full week as President of the United States.
I had my most active day of the year trading. It was also my most profitable. Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead. I started the day with a story re...
After an up-and-down year, this household name is as strong as ever.
Deals already are popping up, and we'll soon have earnings reports from the industry giants.
We toured the company helping design cool workspaces for Fortune 500 companies like Facebook and Microsoft.
Shares of Johnson & Johnson are poised for a rally as the stock is currently trading about 8% off its 52-week high.
Johnson & Johnson could repatriate offshore profits in 2017 if a potential tax holiday is passed.
Animal health and oncology deal activity is heating up in 2017.
After a period of consolidation, several personal care products companies look like they are about to rally.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Disney and Goldman are doing a lot of the heavy lifting.